rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Trulieve Cannabis Corp. Subordinate Voting Shares

TRLV · NYSE

Health CarePharmaceuticalsLeadingCannabis

TRLV stood above a rising 150-day average in 36 of the last 52 weekly readings, including each of the last 25 weeks. It is 8.8% above that average now. Pharmaceuticals: 31% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
25 in a row
Industry in uptrend
31% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$29.3M
Officials’ trades on record
0
Institutions holding
121 (+116)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 36 of 52 weeks.

17 Apr – 16 Oct
26%36%46%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$28.2M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months7
Buyers · sellers0 · 1
WhoDidSharesTraded
Kim A. RiversChairman and CEOsold136,811at $8.7626 Jun 2026filed 26 Jun 2026
Kim A. RiversChairman and CEOsold300,000at $8.1725 Jun 2026filed 25 Jun 2026
Kim A. RiversChairman and CEOsold400,000at $8.1724 Jun 2026filed 25 Jun 2026
Kim A. RiversChairman and CEOsold380,000at $8.4723 Jun 2026filed 25 Jun 2026
Kim A. RiversChairman and CEOsold204,815at $9.3522 Jun 2026filed 22 Jun 2026
Kim A. RiversChairman and CEOsold139,846at $9.4618 Jun 2026filed 22 Jun 2026
Kim A. RiversChairman and CEOsold137,535at $9.3617 Jun 2026filed 22 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders121+116 on the quarter
New · exited117 · 1
Reported value$322.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
AdvisorShares Investments LLCnew · filed 11 Aug 202610,641,152$104.6M+10,641,152
NOMURA HOLDINGS INCnew · filed 14 Aug 20265,065,849$49.8M+5,065,849
CANTOR FITZGERALD, L. P.new · filed 14 Aug 20263,750,000$36.9M+3,750,000
Marex Group Ltdnew · filed 14 Aug 20263,250,000$31.9M+3,250,000
ING GROEP NVnew · filed 13 Aug 20262,665,000$26.2M+2,665,000
JANE STREET GROUP, LLCnew · filed 14 Aug 20261,212,526$11.9M+1,212,526
PICTON MAHONEY ASSET MANAGEMENTnew · filed 13 Aug 2026838,088$8.2M+838,088
Anson Funds Management LPnew · filed 13 Aug 2026524,500$5.6M+524,500
Verition Fund Management LLCnew · filed 14 Aug 2026500,000$4.9M+500,000
MONTANOVA CAPITAL, LLCnew · filed 14 Aug 2026356,100$3.5M+356,100
31 Mar 2023 – 30 Jun 2026
762117Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Kim A. Rivers Company insiderChairman and CEO · last 26 Jun 20265 · 7
Brett R. Walsh Company insiderChief Accounting Officer · last 13 Mar 20260 · 0
Christine Ann Hersey Company insiderChief Corp Affairs & Strategy · last 13 Mar 20260 · 0
Eric Powers Company insiderChief Legal Officer · last 13 Mar 20262 · 0
Jan Reese Company insiderChief Financial Officer · last 13 Mar 20260 · 0
Jane Cecil Morreau Company insiderDirector · last 13 Mar 20261 · 0
Jason Pernell Company insiderPresident · last 13 Mar 20260 · 0
Kyle Landrum Company insiderChief Production Officer · last 13 Mar 20262 · 0
Matthew J. Foulston Company insiderDirector · last 13 Mar 20260 · 0
Nilyum Jhala Company insiderChief Technology Officer · last 13 Mar 20263 · 0
Peter Healy Company insiderDirector · last 13 Mar 20261 · 0
Richard S. May Company insiderDirector · last 13 Mar 20262 · 0

Same industry

ABBV AbbVieLeading+20%
VTRS ViatrisLeading+16%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202560.2%
Operating profit marginFY 2025 · to 31 Dec 202512.1%
Free cash flow marginFY 2025 · to 31 Dec 202519.4%
Return on capital employedFY 2025 · to 31 Dec 20255.6%
Debt to equityFY 2025 · to 31 Dec 20250.12×
Cash and equivalentsFY 2025 · to 31 Dec 2025$255.5M
Free cash flowFY 2025 · to 31 Dec 2025$228.6M

Analyst forecasts

No analyst forecasts yet.